{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:16:03Z","timestamp":1792977363872,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00213-024-06529-5","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T11:02:36Z","timestamp":1705402956000},"page":"209-223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports"],"prefix":"10.1007","volume":"241","author":[{"given":"Mehdi","family":"Akbari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonay","family":"Sheikhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Alijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Kafshchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"issue":"15","key":"6529_CR1","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.3390\/2Fijms20153647","volume":"20","author":"F Ambrogio","year":"2019","unstructured":"Ambrogio F, Martella LA, Odetti P, Monacelli F (2019) Behavioral disturbances in dementia and beyond: time for a new conceptual frame? Int J Mole Sci 20(15):3647. https:\/\/doi.org\/10.3390\/2Fijms20153647","journal-title":"Int J Mole Sci"},{"key":"6529_CR2","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. (2022).\u00a0Diagnostic and statistical manual of mental disorders\u00a0(5th ed., text rev.).\u00a0https:\/\/doi.org\/10.1176\/appi.books.9780890425787","DOI":"10.1176\/appi.books.9780890425787"},{"key":"6529_CR3","doi-asserted-by":"publisher","unstructured":"*Bulbena-Cabr\u00e9 A, Bulbena A (2016) Aripiprazole-induced hypersexuality.Primary Care Companion CNS Disorders 18(6): 26650https:\/\/doi.org\/10.4088\/pcc.16l01983","DOI":"10.4088\/pcc.16l01983"},{"key":"6529_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13567","author":"BG Burk","year":"2023","unstructured":"Burk BG, DiGiacomo T, Polancich S, Pruett BS, Sivaraman S, Birur B (2023) Antipsychotics and obsessive\u2013compulsive disorder\/obsessive\u2013compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system. Acta Psychiatr Scand. https:\/\/doi.org\/10.1111\/acps.13567","journal-title":"Acta Psychiatr Scand"},{"key":"6529_CR5","doi-asserted-by":"publisher","unstructured":"*Ceylan ME, Evrensel A, \u00dcnsalver B\u00d6, C\u00f6mert G (2021) Pathological gambling due to aripiprazole: two cases. West Indian Med J69(3): 154-156https:\/\/doi.org\/10.7727\/wimj.2015.107","DOI":"10.7727\/wimj.2015.107"},{"key":"6529_CR6","doi-asserted-by":"publisher","unstructured":"*Chen HY, Ma CH, Liu CC (2019) Two cases of de novo pathological gambling associated with aripiprazole. Clin Neuropharmacol 42(3): 101-102https:\/\/doi.org\/10.1097\/wnf.0000000000000342","DOI":"10.1097\/wnf.0000000000000342"},{"key":"6529_CR7","doi-asserted-by":"publisher","unstructured":"*Cheon E, Koo BH, Seo SS, Lee JY (2013) Two cases of hypersexuality probably associated with aripiprazole. Psychiatry Inv 10(2): 200https:\/\/doi.org\/10.4306\/pi.2013.10.2.200","DOI":"10.4306\/pi.2013.10.2.200"},{"key":"6529_CR8","doi-asserted-by":"publisher","unstructured":"*\u00c7ildir DA, Kalyoncu T (2018) Trichotillomania associated with aripiprazole: a case report. J Clin Psychopharmacol 38(1): 98-99https:\/\/doi.org\/10.1097\/jcp.0000000000000821","DOI":"10.1097\/jcp.0000000000000821"},{"key":"6529_CR9","doi-asserted-by":"publisher","unstructured":"*Cohen J, Magalon D, Boyer L, Simon N, Lan\u00e7on C (2011) Aripiprazole-induced pathological gambling: a report of 3 cases. Curr Drug Saf 6(1):51-53https:\/\/doi.org\/10.2174\/157488611794480016","DOI":"10.2174\/157488611794480016"},{"key":"6529_CR10","doi-asserted-by":"publisher","unstructured":"*Corbeil O, Corbeil S, Giroux I, Jacques C, Dorval M, Demers MF, Roy MA (2020) Problem gambling associated with aripiprazole in first-episode psychosis patients: a series of 6 case reports. J Clin Psychopharmacol 40(2):191-194https:\/\/doi.org\/10.1007\/s40263-021-00801-4","DOI":"10.1007\/s40263-021-00801-4"},{"issue":"4","key":"6529_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.4088\/2Fpcc.v07n0605","volume":"21","author":"JH Cox","year":"2021","unstructured":"Cox JH, Cavanna AE (2021) Aripiprazole for the treatment of Tourette syndrome. Expert Rev Neurotherapeut 21(4):381\u2013391. https:\/\/doi.org\/10.4088\/2Fpcc.v07n0605","journal-title":"Expert Rev Neurotherapeut"},{"key":"6529_CR12","doi-asserted-by":"publisher","unstructured":"*Das S, Chatterjee SS, Bagewadi V (2017) Aripiprazole induced hypersexuality, when we should be cautious? Asian J Psychiatry 29:162-163https:\/\/doi.org\/10.1016\/j.ajp.2017.05.023","DOI":"10.1016\/j.ajp.2017.05.023"},{"issue":"1","key":"6529_CR13","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10072-021-05324-w","volume":"43","author":"R De Micco","year":"2022","unstructured":"De Micco R, Satolli S, Siciliano M, De Mase A, Giordano A, Tedeschi G, Tessitore A (2022) Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson\u2019s disease patients: a prospective longitudinal study. Neurol Sci 43(1):357\u2013364. https:\/\/doi.org\/10.1007\/s10072-021-05324-w","journal-title":"Neurol Sci"},{"issue":"1","key":"6529_CR14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.21608\/bfsa.2022.239464","volume":"45","author":"F Derakhshanpour","year":"2022","unstructured":"Derakhshanpour F, Deylamsalehi A, Moghadda SSJ, Shahini N (2022) Efficacy of aripiprazole and risperidone in treatment of children with attention-deficit\/hyperactivity disorder: a double-blind clinical trial study. Bull Pharmaceut Sci Assiut 45(1):281\u2013288. https:\/\/doi.org\/10.21608\/bfsa.2022.239464","journal-title":"Bull Pharmaceut Sci Assiut"},{"key":"6529_CR15","doi-asserted-by":"publisher","unstructured":"*Desarkar P, Das A, Nizamie SH (2007) Aripiprazole-induced obsessive-compulsive disorder: a report of 2 cases. J Clin Psychopharmacol 27(3): 305-306https:\/\/doi.org\/10.1097\/01.jcp.0000270091.32286.0a","DOI":"10.1097\/01.jcp.0000270091.32286.0a"},{"key":"6529_CR16","doi-asserted-by":"publisher","unstructured":"*Dhillon R, Bastiampillai T, Cao CZ, Eckert TG, Tibrewal P (2017) Aripiprazole and impulse-control disorders: a recent FDA warning and a case report. Primary Care Companion for CNS Disorders19(1): 26647https:\/\/doi.org\/10.4088\/pcc.16l02003","DOI":"10.4088\/pcc.16l02003"},{"issue":"9","key":"6529_CR17","doi-asserted-by":"publisher","first-page":"pyv047","DOI":"10.1093\/ijnp\/pyv047","volume":"18","author":"M Dold","year":"2015","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S (2015) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol 18(9):pyv047. https:\/\/doi.org\/10.1093\/ijnp\/pyv047","journal-title":"Int J Neuropsychopharmacol"},{"issue":"02","key":"6529_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4103\/jnrp.jnrp_359_16","volume":"8","author":"N Doval","year":"2017","unstructured":"Doval N, Das S, Moun V (2017) Aripiprazole in tardive dyskinesia: is it a safe choice? J Neurosci Rural Practice 8(02):294\u2013295. https:\/\/doi.org\/10.4103\/jnrp.jnrp_359_16","journal-title":"J Neurosci Rural Practice"},{"issue":"4","key":"6529_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1503\/2Fjpn.190053","volume":"44","author":"L Downing","year":"2019","unstructured":"Downing L, Kim DD, Procyshyn RM, Tibbo P (2019) Management of sexual adverse effects induced by atypical antipsychotic medication. J Psychiatry Neurosci 44(4):287\u2013288. https:\/\/doi.org\/10.1503\/2Fjpn.190053","journal-title":"J Psychiatry Neurosci"},{"key":"6529_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-020-01203-z","volume":"19","author":"FT Endomba","year":"2020","unstructured":"Endomba FT, Tankeu AT, Nkeck JR, Tochie JN (2020) Leptin and psychiatric illnesses: Does leptin play a role in antipsychotic-induced weight gain? Lipids Health Dis 19:1\u201312. https:\/\/doi.org\/10.1186\/s12944-020-01203-z","journal-title":"Lipids Health Dis"},{"key":"6529_CR21","doi-asserted-by":"publisher","unstructured":"Faheem M, Akram W, Akram H, Khan MA, Siddiqui FA, Majeed I (2022) Gender-Based Differences in Prevalence and Effects of ADHD in Adults; a Systematic Review. Asian J Psychiatry 103205. https:\/\/doi.org\/10.1016\/j.ajp.2022.103205","DOI":"10.1016\/j.ajp.2022.103205"},{"issue":"9","key":"6529_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/0006-3223(90)90037-3","volume":"27","author":"E Ferrari","year":"1990","unstructured":"Ferrari E, Fraschini F, Brambilla F (1990) Hormonal circadian rhythms in eating disorders. Biol Psychiat 27(9):1007\u20131020. https:\/\/doi.org\/10.1016\/0006-3223(90)90037-3","journal-title":"Biol Psychiat"},{"issue":"2","key":"6529_CR23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1192\/bjp.2021.165","volume":"221","author":"Y Furukawa","year":"2022","unstructured":"Furukawa Y, Hamza T, Cipriani A, Furukawa TA, Salanti G, Ostinelli EG (2022) Optimal dose of aripiprazole for augmentation therapy of antidepressant-refractory depression: Preliminary findings based on a systematic review and dose\u2013effect meta-analysis. Br J Psychiatry 221(2):440\u2013447. https:\/\/doi.org\/10.1192\/bjp.2021.165","journal-title":"Br J Psychiatry"},{"issue":"3","key":"6529_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/pcn.13511","volume":"77","author":"M Fusaroli","year":"2023","unstructured":"Fusaroli M, Giunchi V, Battini V, Gringeri M, Rimondini R, Menchetti M, Poluzzi E (2023) Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study. Psychiatry Clin Neurosci 77(3):160\u2013167. https:\/\/doi.org\/10.1111\/pcn.13511","journal-title":"Psychiatry Clin Neurosci"},{"key":"6529_CR25","doi-asserted-by":"publisher","unstructured":"*Gaboriau L, Victorri-Vigneau C, G\u00e9rardin M, Allain-Veyrac G, Jolliet-Evin P, Grall-Bronnec M (2014) Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addictive Behaviors 39(3) 562-565https:\/\/doi.org\/10.1016\/j.addbeh.2013.11.005","DOI":"10.1016\/j.addbeh.2013.11.005"},{"key":"6529_CR26","doi-asserted-by":"publisher","unstructured":"*Gavaudan G, Magalon D, Cohen J, Lan\u00e7on C, L\u00e9onetti G, P\u00e9lissier\u2010Alicot AL (2010) Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility. J Forensic Sci 55(6):659-1662https:\/\/doi.org\/10.1111\/j.1556-4029.2010.01483.x","DOI":"10.1111\/j.1556-4029.2010.01483.x"},{"issue":"2","key":"6529_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/pra.0000000000000367","volume":"25","author":"YR Giri","year":"2019","unstructured":"Giri YR, Peteru SR (2019) Escalation of gambling associated with aripiprazole: a case report and literature review. J Psychiatric Practice\u00ae 25(2):139\u2013145. https:\/\/doi.org\/10.1097\/pra.0000000000000367","journal-title":"J Psychiatric Practice\u00ae"},{"key":"6529_CR28","doi-asserted-by":"publisher","unstructured":"Goh CMJ, Asharani PV, Abdin E, Shahwan S, Zhang Y, Sambasivam R,... Subramaniam M (2022) Gender differences in alcohol use: a nationwide study in a multiethnic population. Int J Mental Health Addict 1\u201315. https:\/\/doi.org\/10.1007\/s11469-022-00921-y","DOI":"10.1007\/s11469-022-00921-y"},{"key":"6529_CR29","doi-asserted-by":"publisher","unstructured":"*Golouh V, Celofiga A (2021) Pathological Gambling and Compulsive Eating Associated with Long-Acting Injectable Aripiprazole: A Case Report. Psychiatria Danubina 33(3):373\u2013375. https:\/\/doi.org\/10.24869\/psyd.2021.373","DOI":"10.24869\/psyd.2021.373"},{"key":"6529_CR30","doi-asserted-by":"publisher","first-page":"848472","DOI":"10.3389\/fphar.2022.848472","volume":"13","author":"K Guo","year":"2022","unstructured":"Guo K, Feng Z, Chen S, Yan Z, Jiao Z, Feng D (2022) Safety profile of antipsychotic drugs: analysis based on a provincial spontaneous reporting systems Database. Front Pharmacol 13:848472. https:\/\/doi.org\/10.3389\/fphar.2022.848472","journal-title":"Front Pharmacol"},{"key":"6529_CR31","doi-asserted-by":"publisher","unstructured":"*Gupta P, Gupta R, Balhara YPS (2017) Obsessive-compulsive symptoms associated with aripiprazole treatment in bipolar disorder: a case report. J Clin Psychopharmacol 37(1):108 109https:\/\/doi.org\/10.1097\/jcp.0000000000000629","DOI":"10.1097\/jcp.0000000000000629"},{"issue":"1","key":"6529_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12888-023-04617-y","volume":"23","author":"S Hattori","year":"2023","unstructured":"Hattori S, Suda A, Kishida I, Miyauchi M, Shiraishi Y, Noguchi N, Hishimoto A (2023) Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia. BMC Psychiatry 23(1):1\u20137. https:\/\/doi.org\/10.1186\/s12888-023-04617-y","journal-title":"BMC Psychiatry"},{"key":"6529_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s10899-015-9548-8","volume":"32","author":"N Hing","year":"2016","unstructured":"Hing N, Russell A, Tolchard B, Nower L (2016) Risk factors for gambling problems: An analysis by gender. J Gambl Stud 32:511\u2013534. https:\/\/doi.org\/10.1007\/s10899-015-9548-8","journal-title":"J Gambl Stud"},{"key":"6529_CR34","unstructured":"IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp"},{"issue":"2","key":"6529_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","volume":"956","author":"J Ichikawa","year":"2002","unstructured":"Ichikawa J, Li Z, Dai J, Meltzer HY (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956(2):349\u2013357. https:\/\/doi.org\/10.1016\/S0006-8993(02)03570-9","journal-title":"Brain Res"},{"issue":"2","key":"6529_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jare.2015.05.001","volume":"7","author":"J Johnson","year":"2016","unstructured":"Johnson J, El-Alfy AT (2016) Review of available studies of the neurobiology and pharmacotherapeutic management of trichotillomania. J Adv Res 7(2):169\u2013184. https:\/\/doi.org\/10.1016\/j.jare.2015.05.001","journal-title":"J Adv Res"},{"key":"6529_CR37","doi-asserted-by":"publisher","unstructured":"*Jones R, Shad M (20190 Aripiprazole-induced kleptomania: Case report. J Affect Disord 244: 242 243https:\/\/doi.org\/10.1016\/j.jad.2018.05.042","DOI":"10.1016\/j.jad.2018.05.042"},{"issue":"9","key":"6529_CR38","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/jcp.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63(9):763\u2013771. https:\/\/doi.org\/10.4088\/jcp.v63n0903","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"6529_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/2Fnpr2.12180","volume":"41","author":"T Kikuchi","year":"2021","unstructured":"Kikuchi T, Maeda K, Suzuki M, Hirose T, Futamura T, McQuade RD (2021) Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacology Reports 41(2):134\u2013143. https:\/\/doi.org\/10.1002\/2Fnpr2.12180","journal-title":"Neuropsychopharmacology Reports"},{"key":"6529_CR40","doi-asserted-by":"publisher","unstructured":"Kim SW, Shin IS, Kim JM, Youn T, Yang SJ, Hwang MY, Yoon JS (2009) The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. Clin Neuropharmacol 32(4): 224 226https:\/\/doi.org\/10.1097\/wnf.0b013e318184fafd","DOI":"10.1097\/wnf.0b013e318184fafd"},{"issue":"12","key":"6529_CR41","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/2Fs40262-021-01041-x","volume":"60","author":"LA Kneller","year":"2021","unstructured":"Kneller LA, Zubiaur P, Koller D, Abad-Santos F, Hempel G (2021) Influence of CYP2D6 phenotypes on the pharmacokinetics of aripiprazole and dehydro-aripiprazole using a physiologically based pharmacokinetic approach. Clinical Pharmacokinetics 60(12):1569\u20131582. https:\/\/doi.org\/10.1007\/2Fs40262-021-01041-x","journal-title":"Clinical Pharmacokinetics"},{"key":"6529_CR42","doi-asserted-by":"publisher","unstructured":"*Kobayashi N, Takano M (2018) Aripiprazole-induced sleep-related eating disorder: a case report. J Med Case Reports 12(1):1-4https:\/\/doi.org\/10.1186\/s13256-018-1622-2","DOI":"10.1186\/s13256-018-1622-2"},{"key":"6529_CR43","doi-asserted-by":"publisher","unstructured":"Kodama M, Hamamura T (2010) Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting. Int J Neuropsychopharmacol 13(4):549 551https:\/\/doi.org\/10.1017\/S1461145709990976","DOI":"10.1017\/S1461145709990976"},{"key":"6529_CR44","unstructured":"Kopelman JM (2020) The role of Slc1a1 in OCD-relevant behavior and associated neural activity (Doctoral dissertation, University of Pittsburgh). 30163899"},{"issue":"1","key":"6529_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1055\/a-0941-3874","volume":"47","author":"R Kozian","year":"2019","unstructured":"Kozian R (2019) Hypersexuality induced by aripiprazole. Psychiatr Prax 47(1):43\u201345. https:\/\/doi.org\/10.1055\/a-0941-3874","journal-title":"Psychiatr Prax"},{"issue":"4","key":"6529_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/JCP.0000000000001068","volume":"39","author":"A Lachance","year":"2019","unstructured":"Lachance A, Corbeil O, Corbeil S, Chalifour G, Breault AS, Roy MA, Demers MF (2019) Case reports of aripiprazole and problematic gambling in schizophrenia: a critical review of the evidence. J Clin Psychopharmacol 39(4):393\u2013397. https:\/\/doi.org\/10.1097\/JCP.0000000000001068","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"6529_CR47","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cppeds.2018.08.015","volume":"48","author":"M Lamy","year":"2018","unstructured":"Lamy M, Erickson CA (2018) Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders. Curr Probl Pediatr Adolesc Health Care 48(10):250\u2013264. https:\/\/doi.org\/10.1016\/j.cppeds.2018.08.015","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"issue":"29","key":"6529_CR48","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2174\/2F1568026616666160608084834","volume":"16","author":"P Li","year":"2016","unstructured":"Li P, Snyder GL, Vanover EK (2016) Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Topics Med Chem 16(29):3385\u20133403. https:\/\/doi.org\/10.2174\/2F1568026616666160608084834","journal-title":"Curr Topics Med Chem"},{"key":"6529_CR49","doi-asserted-by":"publisher","unstructured":"*Lin C, Chang HM, Huang MC (2020) Aripiprazole-induced obsessive-compulsive symptoms. Taiwanese J Psychiatry 34 1 47https:\/\/doi.org\/10.4103\/TPSY.TPSY_34_19","DOI":"10.4103\/TPSY.TPSY_34_19"},{"issue":"6","key":"6529_CR50","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/13543784.2016.1175431","volume":"25","author":"G Martinotti","year":"2016","unstructured":"Martinotti G, Orsolini L, Fornaro M, Vecchiotti R, De Berardis D, Iasevoli F, Di Giannantonio M (2016) Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. Expert Opinion Inv Drugs 25(6):719\u2013728. https:\/\/doi.org\/10.1080\/13543784.2016.1175431","journal-title":"Expert Opinion Inv Drugs"},{"key":"6529_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11920-019-1015-2","volume":"21","author":"BM Mathes","year":"2019","unstructured":"Mathes BM, Morabito DM, Schmidt NB (2019) Epidemiological and clinical gender differences in OCD. Curr Psychiatry Rep 21:1\u20137. https:\/\/doi.org\/10.1007\/s11920-019-1015-2","journal-title":"Curr Psychiatry Rep"},{"key":"6529_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03007995.2023.2219155","volume":"39","author":"RS McIntyre","year":"2023","unstructured":"McIntyre RS, Such P, Yildirim M, Madera JM, Zhang Z, Larsen F, Harlin M (2023) Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study. Curr Med Res Opinion, (just-accepted) 39:1\u201316. https:\/\/doi.org\/10.1080\/03007995.2023.2219155","journal-title":"Curr Med Res Opinion, (just-accepted)"},{"issue":"13","key":"6529_CR53","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.3390\/jcm11133890","volume":"11","author":"D Merino","year":"2022","unstructured":"Merino D, G\u00e9rard AO, Van Obberghen EK, Ben Othman N, Ettore E, Giordana B, Drici MD (2022) Medications as a trigger of sleep-related eating disorder: a disproportionality analysis. J Clin Med 11(13):3890. https:\/\/doi.org\/10.3390\/jcm11133890","journal-title":"J Clin Med"},{"key":"6529_CR54","doi-asserted-by":"publisher","unstructured":"*Mohan T, Dolan S, Mohan R, Dawson J (2017) Aripiprazole and impulse-control disorders in high-risk patients. Asian J Psychiatr 27:67 68https:\/\/doi.org\/10.1016\/j.ajp.2017.02.015","DOI":"10.1016\/j.ajp.2017.02.015"},{"issue":"4","key":"6529_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/03630240802100051","volume":"47","author":"I Montero","year":"2008","unstructured":"Montero I, Talavera M, Ruiz I (2008) Clinical trials with a new atypical antipsychotic (Aripiprazole): Gender specific information analysis. Women Health 47(4):39\u201351. https:\/\/doi.org\/10.1080\/03630240802100051","journal-title":"Women Health"},{"key":"6529_CR56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/xeb.0000000000000064","volume":"5","author":"S Moola","year":"2017","unstructured":"Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, Mu PF (2017) Chapter 7: Systematic reviews of etiology and risk. Joanna Briggs institute reviewer\u2019s manual. The Joanna Briggs Institute 5:217\u2013269. https:\/\/doi.org\/10.1097\/xeb.0000000000000064","journal-title":"The Joanna Briggs Institute"},{"issue":"12","key":"6529_CR57","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore TJ, Glenmullen J, Mattison DR (2014) Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174(12):1930\u20131933. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5262","journal-title":"JAMA Intern Med"},{"key":"6529_CR58","doi-asserted-by":"publisher","unstructured":"*Mouaffak F, Gallarda T, Bayl\u00e9 FJ, Oli\u00e9 JP, Baup N (2007) Worsening of obsessive-compulsive symptoms after treatment with aripiprazole. J Clin Psychopharmacol 27(2): 237 238https:\/\/doi.org\/10.1097\/01.jcp.0000264981.94614.54","DOI":"10.1097\/01.jcp.0000264981.94614.54"},{"key":"6529_CR59","doi-asserted-by":"publisher","unstructured":"*Mousailidis G, Mehboob R, Papanna B, Bhan-Kotwal S, Shoka A (2020) Hypersexuality and new sexual orientation following aripiprazole use. Prog Neurol Psychiatry 24(1):14 16https:\/\/doi.org\/10.1002\/pnp.556","DOI":"10.1002\/pnp.556"},{"key":"6529_CR60","doi-asserted-by":"publisher","unstructured":"*Nafisa D, Kakunje A (2022) Aripiprazole-induced obsessive\u2013compulsive symptoms. Ind Psychiatry J 31(1):158https:\/\/doi.org\/10.4103\/ipj.ipj_182_20","DOI":"10.4103\/ipj.ipj_182_20"},{"key":"6529_CR61","unstructured":"*Naguy A, Naguy C (2022) Trichotieromania and Alopecia Areata Triggered by Aripiprazole-Methylphenidate Combo in an Autistic Child: The Nexus of Impulsivity-Compulsivity. Psychopharmacol Bull 52(2):157. https:\/\/pubmed.ncbi.nlm.nih.gov\/35721814"},{"key":"6529_CR62","doi-asserted-by":"publisher","unstructured":"*Oberbarnscheidt T, Miller NS, Henry JG (2017) Abilify-Induced Gambling Disorder: A Case Review. Psychiatry 199(2):158\u2013159. https:\/\/doi.org\/10.19080\/JPCR.2017.04.555641","DOI":"10.19080\/JPCR.2017.04.555641"},{"issue":"1","key":"6529_CR63","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1176\/ajp.2007.164.1.172a","volume":"164","author":"PR Padala","year":"2007","unstructured":"Padala PR, Wengel SP, Petty F (2007) Manic episode during treatment with aripiprazole. Am J Psychiatry 164(1):172\u2013173. https:\/\/doi.org\/10.1176\/ajp.2007.164.1.172a","journal-title":"Am J Psychiatry"},{"key":"6529_CR64","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1136\/bmj.n71","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"Int J Surg"},{"key":"6529_CR65","doi-asserted-by":"publisher","unstructured":"*Peterson E, Forlano R (2017) Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. Australas Psychiatry 25 6 614 616https:\/\/doi.org\/10.1177\/1039856217715996","DOI":"10.1177\/1039856217715996"},{"issue":"6","key":"6529_CR66","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1743-6109.2009.01309.x","volume":"6","author":"JG Pfaus","year":"2009","unstructured":"Pfaus JG (2009) Pathways of sexual desire. J Sex Med 6(6):1506\u20131533. https:\/\/doi.org\/10.1111\/j.1743-6109.2009.01309.x","journal-title":"J Sex Med"},{"key":"6529_CR67","doi-asserted-by":"crossref","unstructured":"Pollm\u00e4cher T (2015) Treatment of schizophrenia. In: Wright JA, editor. International Encyclopedia of the Social and Behavioral Sciences. 2nd ed. Elsevier 16\u201320. http:\/\/www.elsevier.com\/locate\/permissionusematerial","DOI":"10.1016\/B978-0-08-097086-8.27064-5"},{"key":"6529_CR68","doi-asserted-by":"publisher","unstructured":"*Priya L, Moorthy B (2021) A Case of Hypersexuality in a Patient Receiving Aripiprazole for Schizophrenia. Case Rep Psychiatry 2021. https:\/\/doi.org\/10.1155\/2F2021\/2F5557211","DOI":"10.1155\/2F2021\/2F5557211"},{"issue":"06","key":"6529_CR69","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-2000-8360","volume":"33","author":"R Ramasubbu","year":"2000","unstructured":"Ramasubbu R, Ravindran A, Lapierre Y (2000) Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry 33(06):236\u2013238. https:\/\/doi.org\/10.1055\/s-2000-8360","journal-title":"Pharmacopsychiatry"},{"key":"6529_CR70","doi-asserted-by":"publisher","unstructured":"*Reddy B, Ali M, Guruprasad S, Das S (2017) Hypersexuality induced by Aripiprazole: Two case reports and review of the literature. Asian J Psychiatr 38: 57 59https:\/\/doi.org\/10.1016\/j.ajp.2017.10.008","DOI":"10.1016\/j.ajp.2017.10.008"},{"key":"6529_CR71","doi-asserted-by":"publisher","unstructured":"*Roxanas MG (2010) Pathological gambling and compulsive eating associated with aripiprazole. Aust N Z J Psychiatry 44(3):291 291 https:\/\/doi.org\/10.3109\/00048670903487282","DOI":"10.3109\/00048670903487282"},{"key":"6529_CR72","doi-asserted-by":"publisher","unstructured":"*Scavone C, Stelitano B, Rafaniello C, Rossi F, Sportiello L, Capuano A (2020) Drugs-induced pathological gambling: an analysis of Italian spontaneous reporting system. J Gambling Stud 36:85-96.https:\/\/doi.org\/10.1007\/s10899-019-09828-1","DOI":"10.1007\/s10899-019-09828-1"},{"key":"6529_CR73","doi-asserted-by":"publisher","unstructured":"*Schlachetzki JC, Langosch JM (2008) Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder? J Clin Psychopharmacol 28(5):567-568https:\/\/doi.org\/10.1097\/jcp.0b013e31818582de","DOI":"10.1097\/jcp.0b013e31818582de"},{"key":"6529_CR74","doi-asserted-by":"publisher","unstructured":"*Smith N, Kitchenham N, Bowden-Jones H (2011) Pathological gambling and the treatment of psychosis with aripiprazole. Br J Psychiatry 199(2):158-159https:\/\/doi.org\/10.1192\/bjp.bp.110.084996","DOI":"10.1192\/bjp.bp.110.084996"},{"issue":"4","key":"6529_CR75","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5937\/scriptamed50-22410","volume":"50","author":"M Stajic","year":"2019","unstructured":"Stajic M (2019) Aripiprazole as a mood stabilizer in postpartum depression with premorbid passive-dependent personality structure. Scr Med 50(4):188\u2013190. https:\/\/doi.org\/10.5937\/scriptamed50-22410","journal-title":"Scr Med"},{"key":"6529_CR76","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3389\/fpsyt.2020.00318","volume":"11","author":"MI Stefanou","year":"2020","unstructured":"Stefanou MI, Vittore D, Wolz I, Klingberg S, Wildgruber D (2020) Recurrent episodes of paraphilic behavior possibly associated with olanzapine and aripiprazole treatment in a patient with schizophrenia. Front Psych 11:318. https:\/\/doi.org\/10.3389\/fpsyt.2020.00318","journal-title":"Front Psych"},{"issue":"1","key":"6529_CR77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s43440-022-00440-6","volume":"75","author":"A Stelmach","year":"2023","unstructured":"Stelmach A, Guzek K, Ro\u017cnowska A, Najbar I, Sadakierska-Chudy A (2023) Antipsychotic drug\u2014Aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms. Pharmacol Rep 75(1):19\u201331. https:\/\/doi.org\/10.1007\/s43440-022-00440-6","journal-title":"Pharmacol Rep"},{"issue":"Suppl 1","key":"6529_CR78","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.4103\/psychiatry.IndianJPsychiatry_519_18","volume":"61","author":"A Thamby","year":"2019","unstructured":"Thamby A, Jaisoorya TS (2019) Antipsychotic augmentation in the treatment of obsessive-compulsive disorder. Indian J Psychiatry 61(Suppl 1):S51. https:\/\/doi.org\/10.4103\/psychiatry.IndianJPsychiatry_519_18","journal-title":"Indian J Psychiatry"},{"key":"6529_CR79","doi-asserted-by":"publisher","first-page":"204512532211132","DOI":"10.1177\/20451253221113238","volume":"12","author":"Y Tien","year":"2022","unstructured":"Tien Y, Huang HP, Liao DL, Huang SC (2022) Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan. Therapeut Adv Psychopharmacol 12:20451253221113240. https:\/\/doi.org\/10.1177\/20451253221113238","journal-title":"Therapeut Adv Psychopharmacol"},{"issue":"5","key":"6529_CR80","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.eurpsy.2007.01.001","volume":"22","author":"A \u00dc\u00e7ok","year":"2007","unstructured":"\u00dc\u00e7ok A, \u0130ncesu C, Aker T, Erko\u00e7 \u015e (2007) Sexual dysfunction in patients with schizophrenia on antipsychotic medication. Eur Psychiatry 22(5):328\u2013333. https:\/\/doi.org\/10.1016\/j.eurpsy.2007.01.001","journal-title":"Eur Psychiatry"},{"key":"6529_CR81","doi-asserted-by":"publisher","unstructured":"*Usmani MA (2020) Aripiprazole induced compulsive eating in adolescent: Is this the effect of aripiprazole on Serotonin receptors? J Clin Rev Case Rep 5(7):306\u2013308. https:\/\/doi.org\/10.33140\/JCRC","DOI":"10.33140\/JCRC"},{"issue":"3","key":"6529_CR82","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1192\/bjp.187.3.235","volume":"187","author":"E Vieta","year":"2005","unstructured":"Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Iwamoto T (2005) Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 187(3):235\u2013242. https:\/\/doi.org\/10.1192\/bjp.187.3.235","journal-title":"Br J Psychiatry"},{"issue":"1","key":"6529_CR83","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40290-022-00453-9","volume":"37","author":"M Wolfschlag","year":"2023","unstructured":"Wolfschlag M, H\u00e5kansson A (2023) Drug-Induced Gambling Disorder: Epidemiology, Neurobiology, and Management. Pharmaceut Med 37(1):37\u201352. https:\/\/doi.org\/10.1007\/s40290-022-00453-9","journal-title":"Pharmaceut Med"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-024-06529-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-024-06529-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T04:12:04Z","timestamp":1705983124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-024-06529-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6529"],"URL":"https:\/\/doi.org\/10.1007\/s00213-024-06529-5","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"27 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}